Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Any CCR4 positivity was seen in all CD8+ MF cases, in 83% of CD30+ LPD cases, in 75% of AETCL cases, in 33% of GDTCL cases, and in none of the SPTCL cases.
|
31355940 |
2020 |
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Lymphomatoid papulosis (LyP) is a benign chronic often relapsing skin condition that belongs to the CD30-positive cutaneous lymphoproliferative disorders.
|
31494989 |
2020 |
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Unlike CD30+ cutaneous LPD, BIA-ALCL cannot be readily observed over time to study the different steps in progression to ALCL.
|
31577659 |
2020 |
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
These were considered in four main categories: primary cutaneous B cell lymphomas (12 cases), primary cutaneous T cell lymphomas/lymphoproliferations with CD8+/cytotoxic phenotype (12 cases), primary cutaneous CD30-positive lymphoproliferative disorders (15 cases) and primary cutaneous T cell lymphomas/leukaemias with CD4+ phenotype (4 cases).
|
31781845 |
2019 |
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Non-MF/SS PCLs were primarily of T-cell origin (61%) where CD30+ lymphoproliferative disorders predominated, followed by Epstein-Barr virus-induced lymphomas, and peripheral T-cell lymphomas, not otherwise specified.
|
28400635 |
2019 |
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Primary cutaneous CD8+ and CD30+ T-cell lymphoproliferative disorders: case reports and clinical implications.
|
30670369 |
2019 |
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CD30+ lymphoproliferative disorders (LD) represent a spectrum of entities ranging from self-limited proliferations or cutaneous lesions with favorable prognosis, such as lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma (ALCL), to more aggressive malignancies such as systemic ALK-positive and ALK-negative ALCL.
|
31705818 |
2019 |
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Clinicopathologic and microenvironmental analysis of primary cutaneous CD30-positive lymphoproliferative disorders: a 26 year experience from an academic medical center in Brazil.
|
31640798 |
2019 |
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies.
|
30630983 |
2019 |
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Cutaneous CD30+ lymphoproliferative disorders constitute many cutaneous T-cell lymphomas and comprise lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma (ALCL).Both have an excellent prognosis.
|
31466587 |
2019 |
Lymphoproliferative Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The most frequent CTCL subtypes, in decreasing order of prevalence, were mycosis fungoides (MF), including its variants (75.7%); CD30+ primary cutaneous lymphoproliferative disorders (7.2%); and Sézary syndrome (SS) (3.1%).
|
30294921 |
2019 |
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Mycosis Fungoides Associated With Lesions in the Spectrum of Primary Cutaneous CD30+ Lymphoproliferative Disorders: The Same Process or 3 Coexisting Lymphomas?
|
30946099 |
2019 |
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
At present, brentuximab vedotin, an antibody-drug conjugate composed of an anti-cluster of differentiation (CD)-30 antibody covalently linked to monomethyl auristatin E, is approved for the treatment of CD30+ lymphoproliferative disorders [lymphomatoid papulosis (LyP) and primary cutaneous-anaplastic large-cell lymphoma (pc-ALCL)] as well as transformed CD30+ mycosis fungoides (MF).
|
30430444 |
2019 |
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Low-dose total skin electron beam therapy for refractory cutaneous CD30 positive lymphoproliferative disorders.
|
31179774 |
2019 |
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
TUGSE lesions may mimic malignancy such as squamous cell carcinoma, CD30 positive lymphoproliferative disorder, or infectious diseases such as primary syphilis, tuberculosis, or Epstein-Barr virus mucocutaneous ulcer.
|
31706333 |
2019 |
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CCR3 was expressed in 73% of cases of CD30+ lymphoproliferative disorders such as lymphomatoid papulosis and anaplastic large cell lymphoma.
|
31045236 |
2019 |
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Brentuximab vedotin is a very interesting new treatment for advanced tumor MF, Sezary syndrome, and primary cutaneous CD30+ lymphoproliferative disorders.
|
28400633 |
2019 |
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Prospective, nonblinded survey design utilizing questionnaires including panels of QoL indices obtained from 105 patients with mycosis fungoides, Sezary syndrome, and CD30+ lymphoproliferative disorder.
|
30074622 |
2018 |
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Whereas none of the patients in our index series exhibited EBV positivity, here we discuss a very unique example of a 14-year-old girl diagnosed with EBV positive CD30 positive lymphoproliferative disorder strongly resembling the cases of intra-oral type C lymphomatoid papulosis.
|
30292067 |
2018 |
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Another photoresponsive CTCL variant is lymphomatoid papulosis (LP), a CD30+ lymphoproliferative disease characterised by chronically recurring papules.
|
30325389 |
2018 |
Lymphoproliferative Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Fifteen patients with an established diagnosis of cutaneous lymphoma were prospectively recruited and seen in the university multidisciplinary cutaneous lymphoma program with MF, an MF- variant, CD30-positive lymphoproliferative disorder, or cutaneous B-cell lymphomas and were included in our study.
|
29318585 |
2018 |
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
In order of frequency, diagnoses were: mycosis fungoides (40.5%), peripheral T-cell lymphoma not otherwise specified (22.95%), adult T-cell lymphoma/leukemia (18.9%), CD30+ lymphoproliferative disorders (6.8%), hydroa vacciniforme-like lymphoma (5.4%), extranodal NK/T-cell lymphoma (4.1%) and Sézary syndrome (1.4%).
|
29166501 |
2018 |
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Cutaneous CD30-positive T-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment.
|
29719017 |
2018 |
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
PCH predominantly occurs in CD30-positive lymphoproliferative disorders.
|
29473196 |
2018 |
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Lymphomatoid papulosis is one of the primary cutaneous CD30+ T-cell lymphoproliferative disorders.
|
28614957 |
2018 |